# GRAIL Inc. (GRAL) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $139.44, market value $6.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). GRAIL Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 37.7×**. Each dollar of revenue is priced at 37.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.4×**. The shares trade at 2.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -4.8%** (5-yr avg -55.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -338.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -277.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: -15.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: -13.4%**. Each dollar of assets produces -13.4% of profit.

## Growth
- **Revenue growth (1 yr): 17.2%** (3-yr 38.4%/yr). Revenue grew 17.2% over the last year.
- **EPS growth (1 yr): 82.5%**. Earnings per share rose 82.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 11.97** (quick 11.97). Current assets cover the next year's liabilities 11.97 times.
- **Altman Z-score: 11.87**. A Z-score of 11.87 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. GRAIL Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover GRAIL Inc.; the consensus is buy, with an average price target of $132.56 (-5% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 45.5%** (YTD 56.3%, 3-mo 90.4%). The shares are up 45.5% over twelve months including dividends.
- **From 52-week high: -16.2%** (236.0% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 2.99** (volatility 102%). Beta of 2.99 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GRAL · Page: https://foliofundamentals.com/stocks/gral

Not investment advice.